Literature DB >> 30578404

Myelosuppression with Oxazolidinones: Are There Differences?

Cathy Hardalo1, Thomas P Lodise2, Carisa De Anda3.   

Abstract

Entities:  

Keywords:  myelosuppression; oxazolidinones

Mesh：

Substances：

Year:  2018        PMID： 30578404      PMCID： PMC6325221          DOI： 10.1128/AAC.01833-18

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN： 0066-4804            Impact factor:   5.191


× No keyword cloud information.
  12 in total

1.  Addressing the issue of channeling bias in observational studies with propensity scores analysis.

Authors:  Francis S Lobo; Samuel Wagner; Cynthia R Gross; Jon C Schommer
Journal:  Res Social Adm Pharm       Date:  2006-03

Review 2.  Data mining for signals in spontaneous reporting databases: proceed with caution.

Authors:  Wendy P Stephenson; Manfred Hauben
Journal:  Pharmacoepidemiol Drug Saf       Date:  2007-04       Impact factor: 2.890

3.  Thrombocytopenia with Tedizolid and Linezolid.

Authors:  Erica Yookyung Lee; Aisling R Caffrey
Journal:  Antimicrob Agents Chemother       Date:  2017-12-21       Impact factor: 5.191

4.  Efficacy, safety and pharmacokinetics of tedizolid versus linezolid in patients with skin and soft tissue infections in Japan - Results of a randomised, multicentre phase 3 study.

Authors:  Hiroshige Mikamo; Yoshio Takesue; Yuji Iwamoto; Takahiko Tanigawa; Masaharu Kato; Yoko Tanimura; Shigeru Kohno
Journal:  J Infect Chemother       Date:  2018-03-09       Impact factor: 2.211

5.  Replication of the Weber effect using postmarketing adverse event reports voluntarily submitted to the United States Food and Drug Administration.

Authors:  Nicole R Hartnell; James P Wilson
Journal:  Pharmacotherapy       Date:  2004-06       Impact factor: 4.705

6.  Tedizolid phosphate vs linezolid for treatment of acute bacterial skin and skin structure infections: the ESTABLISH-1 randomized trial.

Authors:  Philippe Prokocimer; Carisa De Anda; Edward Fang; Purvi Mehra; Anita Das
Journal:  JAMA       Date:  2013-02-13       Impact factor: 56.272

Review 7.  Clinical Pharmacokinetics and Pharmacodynamics of Oxazolidinones.

Authors:  Claire Roger; Jason A Roberts; Laurent Muller
Journal:  Clin Pharmacokinet       Date:  2018-05       Impact factor: 6.447

8.  Platelet profile in patients with acute bacterial skin and skin structure infections receiving tedizolid or linezolid: findings from the Phase 3 ESTABLISH clinical trials.

Authors:  Thomas P Lodise; Edward Fang; Sonia L Minassian; Philippe G Prokocimer
Journal:  Antimicrob Agents Chemother       Date:  2014-09-22       Impact factor: 5.191

9.  Characterization of the haematological profile of 21 days of tedizolid in healthy subjects.

Authors:  Thomas P Lodise; Monique R Bidell; Shawn D Flanagan; Evan J Zasowski; Sonia L Minassian; Philippe Prokocimer
Journal:  J Antimicrob Chemother       Date:  2016-06-17       Impact factor: 5.790

Review 10.  Data mining of the public version of the FDA Adverse Event Reporting System.

Authors:  Toshiyuki Sakaeda; Akiko Tamon; Kaori Kadoyama; Yasushi Okuno
Journal:  Int J Med Sci       Date:  2013-04-25       Impact factor: 3.738
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.